Vanda jumps as FDA lifts tradipitant partial clinical hold

 Shares of Vanda Pharmaceuticals (VNDA) jumped approximately 7% in after-hours trading following the FDA's decision to lift the partial clinical hold on tradipitant, a treatment for motion sickness. The FDA recognized motion sickness as an acute condition, thus eliminating the requirement for an additional six-month toxicity study in dogs. This move addresses previous safety concerns and facilitates the drug’s development. Additionally, the FDA is expected to decide on tradipitant's New Drug Application for preventing nausea-induced vomiting by December 30.

https://www.gurufocus.com/news/3235073/vanda-pharmaceuticals-vnda-soars-after-fda-lifts-tradipitant-hold